Intensity-modulated radiation therapy (IMRT) versus 3-dimensional conformal radiation therapy (3D-CRT) for head and neck cancer: cost-effectiveness analysis
Carregando...
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
ASSOC MEDICA BRASILEIRA
Autores
Citação
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, v.64, n.4, p.318-323, 2018
Resumo
BACKGROUND: A cost-effectiveness analysis of IMRT compared to 3D-CRT for head and neck cancer patients (HNCPs) was conducted in the Brazilian Public Health System. METHODS: A Markov model was used to simulate radiation therapy-induced dysphagia and xerostomia in HNCPs. Data from the PARSPORT trial and the quality-of-life study were used as parameters. The incremental cost-effectiveness ratio (ICER) and cost per quality-adjusted life-year (QALY) gained were calculated. RESULTS: At 2 years, IMRT was associated with an incremental benefit of 0.16 QALYs gained per person, resulting in an ICER of BRL 31,579 per QALY gained. IMRT was considered cost-effective when using the guideline proposed by the World Health Organization (WHO) of three times the national gross domestic product (GDP) per capita (BRL 72,195). Regarding life expectancy (15 years), the incremental benefit of IMRT was 1.16 QALYs gained per person, with an ICER of BRL 4,341. IMRT was also cost-effective using the WHO definition, which states that the maximum cost is equal to the GDP per capita (BRL 24,065). CONCLUSIONS: IMRT was considered cost-effective from the perspective of the Brazilian public health system.
Palavras-chave
Head and neck neoplasms, Radiotherapy, intensity-modulated, Radiotherapy, conformal, Cost-benefit analysis
Referências
- Boyer AL, 2001, INT J RADIAT ONCOL, V51, P880
- de Moraes FY, 2015, INT J RADIAT ONCOL, V92, P707, DOI 10.1016/j.ijrobp.2014.12.063
- Eisbruch A, 2010, INT J RADIAT ONCOL, V76, P1333, DOI 10.1016/j.ijrobp.2009.04.011
- Guadagnolo BA, 2010, CANCER-AM CANCER SOC, V116, P3505, DOI 10.1002/cncr.25205
- Gupta T, 2012, RADIOTHER ONCOL, V104, P343, DOI 10.1016/j.radonc.2012.07.001
- Jensen SB, 2010, SUPPORT CARE CANCER, V18, P1061, DOI 10.1007/s00520-010-0837-6
- Kam MKM, 2007, J CLIN ONCOL, V25, P4873, DOI 10.1200/JCO.2007.11.5501
- Kohler RE, 2013, INT J RADIAT ONCOL, V87, P683, DOI 10.1016/j.ijrobp.2013.08.011
- Lee HS, 2014, BRIT J ORAL MAX SURG, V52, P179, DOI 10.1016/j.bjoms.2013.11.002
- MacFarlane M, 2016, RADIOTHER ONCOL, V119, P331, DOI 10.1016/j.radonc.2016.03.010
- Marta GN, 2015, EUR J CANCER, V51, P2596, DOI 10.1016/j.ejca.2015.08.007
- Marta GN, 2015, ORAL ONCOL, V51, P1069, DOI 10.1016/j.oraloncology.2015.10.009
- Marta GN, 2014, RADIOTHER ONCOL, V110, P9, DOI 10.1016/j.radonc.2013.11.010
- Mendez LC, 2016, EXPERT REV ANTICANC, V16, P99, DOI 10.1586/14737140.2016.1121111
- Merlotti A, 2014, RADIAT ONCOL, V9, P264
- Miles EA, 2005, RADIOTHER ONCOL, V77, P241, DOI 10.1016/j.radonc.2005.10.011
- Nutting CM, 2011, LANCET ONCOL, V12, P127, DOI 10.1016/S1470-2045(10)70290-4
- Nutting CM, 2001, RADIOTHER ONCOL, V60, P173, DOI 10.1016/S0167-8140(01)00382-6
- O'Sullivan B, 2016, LANCET ONCOL, V17, P440, DOI 10.1016/S1470-2045(15)00560-4
- Peng G, 2012, RADIOTHER ONCOL, V104, P286, DOI 10.1016/j.radonc.2012.08.013
- Peponi E, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-1
- Pow EHN, 2006, INT J RADIAT ONCOL, V66, P981, DOI 10.1016/j.ijrobp.2006.06.013
- Ramaekers BLT, 2011, ORAL ONCOL, V47, P768, DOI 10.1016/j.oraloncology.2011.05.012
- Schoenfeld GO, 2008, INT J RADIAT ONCOL, V71, P377, DOI 10.1016/j.ijrobp.2007.10.010
- Sheets NC, 2014, AM J CLIN ONCOL-CANC, V37, P539, DOI 10.1097/COC.0b013e318282a850
- Van de Werf E, 2009, RADIOTHER ONCOL, V93, P137, DOI 10.1016/j.radonc.2009.07.007
- van Rij CM, 2008, RADIAT ONCOL, V3, DOI 10.1186/1748-717X-3-41
- World Health Organization, WHO GUID COST EFF AN
- Yong JHE, 2012, CLIN ONCOL-UK, V24, P532, DOI 10.1016/j.clon.2012.05.010